Journal
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
Volume 13, Issue 4, Pages 241-251Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1074248408325404
Keywords
antimuscarinic; darifenacin; heart rate; overactive bladder; tolterodine
Funding
- Novartis Pharmaceuticals Corporation
Ask authors/readers for more resources
Antimuscarinics, used commonly to treat overactive bladder, may differ in their potential to increase heart rate via effects on cardiac muscarinic M-2 receptors. This prospective, 3-way crossover, randomized, double-blind study assessed the heart rate effects of 7 days' exposure to a nonselective M-2/M-3 receptor blocker (tolterodine; 4 mg/d), a highly selective M-3 receptor blocker (darifenacin; 15 mg/d), and placebo in 162 healthy participants >= 50 years. Heart rate was measured by 24-hour Holter monitoring. Tolterodine significantly increased heart rate versus darifenacin and heart rate versus placebo, while darifenacin did not affect heart rate versus placebo. The proportion of participants with an increase in mean heart rate per 24 hours of >= 5 beats per minute was higher with tolterodine than with darifenacin (P = .0004) or with placebo (P = .0114) but did not differ between darifenacin and placebo. The results show that antimuscarinics exert differential effects on heart rate depending on their muscarinic receptor profile. This should be considered when selecting a treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available